J&J chief hints at unease in China, but plots new buyouts

Johnson & Johnson CEO Alex Gorsky

Johnson & Johnson CEO Alex Gorsky likes to hint at trouble developing its Chinese sales, but don't expect him to come right out and criticize the prickly Chinese government. In a brief interview with The Wall Street Journal, Gorsky said J&J ($JNJ) was looking for new acquisitions in China, with new drugs for lung cancer as one of its top targets. (Lung cancer is particularly prevalent in China, making it a favorite for all the biopharma companies operating there.) And he added that the company is concerned that it takes twice as long to develop a drug in China as it does in the U.S. and Europe. There are times when J&J feels it is facing unfair competition--a possible reference to the Chinese government's move to target foreigners in a recent corruption probe--but Gorsky isn't going into any details. Instead, he reverts to the party line: "We support government actions in creating a leveled playing field for all companies." Story (sub. req.)

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.